Aging Mammalian Tissues In Vitro (R21 Clinical Trial Not Allowed)
This notice of funding opportunity (NOFO) invites applications that propose interdisciplinary research that aims to develop complex mammalian 3-dimensional (3D)in vitromicrophysiological systems (MPS) to model aging and recapitulate aging processes/phenotypes observed in the whole organismin vivo.
This NOFO is primarily focused on human cell-derived MPS (e.g., tissue chip, organ-on-chip, tissue organoids).
However, systems developed using cells of nonhuman mammalian origin are acceptable for benchmarking, system validation, or when their relevance to understanding human aging biology is justified.
Supported projects will be expected to advance the adoption of MPS in aging biology research and as new human-relevant tools for drug discovery.
This NOFO uses the R21 activity code, which is intended for exploratory research at the early and conceptual stages of project development.
Preliminary data are not required.
An essential feature of responsive applications is the adoption of a multidisciplinary approach that includes expertise in aging biology and from disciplines such as stem cell biology, tissue and organ physiology, microfluidics, bioengineering, computational biology, pharmacology, and biostatistics.
This NOFO is primarily focused on human cell-derived MPS (e.g., tissue chip, organ-on-chip, tissue organoids).
However, systems developed using cells of nonhuman mammalian origin are acceptable for benchmarking, system validation, or when their relevance to understanding human aging biology is justified.
Supported projects will be expected to advance the adoption of MPS in aging biology research and as new human-relevant tools for drug discovery.
This NOFO uses the R21 activity code, which is intended for exploratory research at the early and conceptual stages of project development.
Preliminary data are not required.
An essential feature of responsive applications is the adoption of a multidisciplinary approach that includes expertise in aging biology and from disciplines such as stem cell biology, tissue and organ physiology, microfluidics, bioengineering, computational biology, pharmacology, and biostatistics.
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $20,175
Office: National Institutes of Health
Estimated Funding: $20,175
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-26-014.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; U. S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-26-014.html
Contact:
Agency Email Description:
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Agency Email:
Date Posted:
2025-08-26
Application Due Date:
Archive Date:
2025-11-25
Social Entrepreneurship
Spotlight
When it Comes to Social Enterprises, Failure is the Best Platform for Innovation
In the world of social enterprises, failure is a cringe-worthy moment nobody wants to talk about. But, social entrepreneurs can benefit from their failures.
Learn How to Identify and Avoid Grant Scams
